Exhibit 4.12
[LOGO] AusIndustry(TM)
R&D Start Program
Grant Agreement
Particular Conditions
--------------------------------------------------------------------------------
Parties
--------------------------------------------------------------------------------
Commonwealth of Australia acting
through the Industry Research and
Development Board
ABN 51 835 430 479 001
(Department of Industry, Tourism and
Resources)
Postal address Department of Industry, Tourism and Resources
▇▇▇ ▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇
--------------------------------------------------------------------------------
The Grantee
Prana Biotechnology Limited
- ABN 37080699065
- ACN 080 699 065
- postal address ▇▇▇▇▇ ▇
▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇
- business address ▇▇▇▇▇ ▇
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇
--------------------------------------------------------------------------------
R&D Start Grant Agreement
Particular Conditions 1 SME Agreement Version 7
Version 7.2 - Release Date December 2002
Author: R&D Start Program Management
Operative provisions
1. This Grant is made to the Grantee in respect of the Project by the
Industry Research and Development Board on behalf of the Commonwealth to
the Grantee under the R&D Start Program.
2. The Grant is made pursuant to the Industry Research and Development ▇▇▇
▇▇▇▇ and the relevant Ministerial Directions issued under sections 19 and
20 of that Act.
3. The Grant is made on the terms and conditions of the Grant Agreement,
which comprises the General Conditions (version 7.2) and the Particular
Conditions (including the schedule).
4. The Grantee acknowledges that it has received and read a copy of the
General Conditions (version 7-2), and agrees that the terms and conditions
of the General Conditions form part of the Grant Agreement.
5. Terms defined in the General Conditions (version 7.2) have the same
meaning in the Particular Conditions.
6. If there is an inconsistency between the Particular Conditions and the
General Conditions (version 7.2), the Particular Conditions prevail to the
extent of the inconsistency.
R&D Start Grant Agreement
Particular Conditions 2 SME Agreement Version 7
Version 7.2 - Release Date December 2002
Author: R&D Start Program Management
--------------------------------------------------------------------------------
Acceptance of terms
--------------------------------------------------------------------------------
EXECUTED as a deed )
)
Date of deed: )
)
Ensure the applicant does not date the )
Deed, this is done by the )
Commonwealth )
Commonwealth of Australia )
)
SIGNED for and on behalf of the )
COMMONWEALTH OF AUSTRALIA by )
)
a delegate of the INDUSTRY RESEARCH )
AND DEVELOPMENT BOARD in the )
presence of: )
)
------------------------------------- )
Signature of witness )
) [SEAL]
------------------------------------- )
Name of witness (block letters) ) ----------------------------------
This signature block is for customers that have a Common Seal. Please delete if
not necessary
Grantee
The terms and conditions pursuant to which the Grant is made are hereby accepted
by the Grantee.
)
THE COMMON SEAL of )
Prana Biotechnology Limited )
is affixed in the presence of: )
)
)
/s/ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ) /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇
------------------------------------- ) ---------------------------------
Signature of director ) Signature of director/secretary
)
)
▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ ) ▇▇▇▇▇▇ ▇▇▇▇▇▇
------------------------------------- ) ---------------------------------
Name of director (block letters) ) Name of director/secretary (block
) letters)
)
)
R&D Start Grant Agreement
Particular Conditions 3 SME Agreement Version 7
Version 7.2 - Release Date December 2002
Author: R&D Start Program Management
The Schedule
--------------------------------------------------------------------------------
1 Project Title MPAC therapies for Alzheimer's disease.
2 Project Reference Number GRA02960
3 Project Duration
(a) Commencement Date: 1 September 2003
(b) Completion Date: 31 August 2005
4 Grant A maximum amount of $1,359,810
5 Grant Percentage of Eligible
Expenditure 50%
6 Interest Rates 5.65% per annum
7 Project Planned Eligible Expenditure by Financial Year
--------------------------------------------------------------------------
Head of Estimated Expenditure $ Total $
Expenditure
--------------------------------------------------------------------------
2002/03 2003/04 2004/05 2005/06
--------------------------------------------------------------------------
R&D Salary NIL 32,000 39,936 6,912 78,848
Expenditure
--------------------------------------------------------------------------
Contract NIL 813,605 1,401,760 289,256 2,504,621
Expenditure
--------------------------------------------------------------------------
Plant NIL NIL NIL NIL NIL
Expenditure
--------------------------------------------------------------------------
Prototype NIL NIL NIL NLL NIL
Expenditure
--------------------------------------------------------------------------
Other NIL 51,625 76,943 7,578 136,151
Expenditure
--------------------------------------------------------------------------
Project Eligible NIL 897,230 1,518,644 303,746 2,719,620
Expenditure
--------------------------------------------------------------------------
Annual Cap NIL 448,615 759,322 151,873 1,359,810
Amount
--------------------------------------------------------------------------
8 Initial Payment $177,939
R&D Start Grant Agreement
Particular Conditions 4
Version 7.2 - Release Date December 2002
Author: R&D Start Program Management
9 Project Description and Planned Outcomes
To progress the lead MPAC compound PBT-2, developed in R&D Start Project
GRA01809, through pre clinical and clinical phase 1 trials for the Alzheimer's
Disease.
10 Performance Milestones and Planned Achievement Dates
--------------------------------------------------------------------------
Major Milestone Expected Achievement
Date
--------------------------------------------------------------------------
1 Completion of preclinical studies of lead MPAC for 30 September 2004
Alzheimer's Disease.
--------------------------------------------------------------------------
2 Completion of Phase 1 clinical studies of MPAC's 31 August 2005
for Alzheimer's Disease.
--------------------------------------------------------------------------
11 Retention Amount $67,991
12 Reports
-------------------------------------------------------------------------------------
Review Type Due Date Report Period Audit
Report
Y/N
-------------------------------------------------------------------------------------
Progress 28 January 2004 28 November 2003 to 31 December 2003
-------------------------------------------------------------------------------------
Progress 28 April 2004 1 January 2004 to 31 March 2004
-------------------------------------------------------------------------------------
Progress 28 July 2004 1 April 2004 to 30 June 2004
-------------------------------------------------------------------------------------
Progress 28 October 2004 1 July 2004 to 30 September 2004 Y
-------------------------------------------------------------------------------------
Progress 28 January 2005 1 October 2004 to 31 December 2004
-------------------------------------------------------------------------------------
Progress 28 April 2005 1 January 2005 to 31 March 2005
-------------------------------------------------------------------------------------
Progress 28 July 2005 1 April 2005 to 30 June 2005
-------------------------------------------------------------------------------------
Final 28 September 2005 1 July 2005 to 31 August 2005 Y
-------------------------------------------------------------------------------------
Reports must conform with the requirements in the Project Reporting Guide
supplied to the Grantee by the Commonwealth, as varied from time to time by the
Commonwealth and notified to the Grantee.
Unless the. Grantee is otherwise notified by the Commonwealth, commercialisation
reports will be required 1, 3 and 5 years after completion of the Project, in
the format supplied by the Commonwealth at those times.
13 Notices
Notices must be addressed as follows:
a) if given to the Commonwealth, addressed and forwarded to the Director,
AusIndustry State Office, Department of Industry, Tourism and Resources
for the attention of an AusIndustry Customer Service Manager at the
following address:
R&D Start Grant Agreement
Particular Conditions 5 SME Agreement Version 7
Version 7.2 - Release Date December 2002
Author: R&D Start Program Management
Address: ▇▇▇ ▇▇▇ ▇▇▇
▇▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇▇
Facsimile No: 03 9268 7599
or as otherwise notified in writing by an AusIndustry Customer Service Manager;
and
b) if given by the Commonwealth, signed by an authorised delegate of the
Industry Research and Development Board and forwarded to the Grantee at
the following address:
Prana Biotechnology Limited
Mr R ▇▇▇▇▇▇▇
Chief Operating Officer
▇▇▇▇▇ ▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇ ▇▇▇▇
or as otherwise notified in writing by the Grantee.
14 Special Conditions
1. Prana Biotechnology providing satisfactory documentary evidence of its
ability to meet its share of project costs beyond June 2004
2. Prana Biotechnology Limited demonstrating the successful completion of
preclinical evaluation studies in Alzheimer's Disease as noted in major
activities 1 and 2.
R&D Start Grant Agreement
Particular Conditions 6 SME Agreement Version 7
Version 7.2 - Release Date December 2002
Author: R&D Start Program Management
NATIONAL BENEFIT INDICATORS - COMMERCIALISATION
The Industry Research and Development (IR&D) Board understands the increasing
global nature of business and the need for innovative companies to respond
flexibly to market needs. For example, while the IR&D Board is keen to support
projects which involve manufacturing or production in Australia, it accepts that
there will be instances where Australian manufacture could limit the
commercialisation prospects of intellectual property developed with its grant
funding. This does dot remove the necessity for the commercialisation of project
outcomes to provide national benefits,
Set out below are the indicators by which the IR&D Board will assess the level
of national benefit contribution to Australia and the Australian economy from
the commercialisation of R&D Start projects where commercialisation will not
take place in Australia:
o the commercialisation plan includes Australia being maintained as the home
base far future R&D, manufacture or product development;
o the ongoing development of the commercial outcomes, (product, process or
service), arising from R&D activities involves interactions with other
firms and research institutions (both domestic and international);
o the commercialisation of the products, processes or services arising from
R&D activities result in an increase in the number of employees in the
company's operations based in Austrilia;
o as a result of the commercialisation, Australian residents receive
commercial compensation through royalties, licence fees, equity, dividends
or outright sale; and
o production overseas could be considered reasonable as:
> local production is demonstrated to be uneconomic in terms of cost
structure; and/or
> the production or commercialisation requires close physical
interaction with overseas companies, customers, suppliers and
competitors.
Where a company is proposing to conduct exploitation overseas due to economic
viability in terms of cost structure, the Board will consider:
o the level of commitment to retaining or enhancing the companies R&D
facilities in Australia;
o the degree of globalisation of the relevant industry sector;
o the relative input costs to production as identified by the company;
o the relative transport costs as identified by the company;
o the relative costs of skilled labour as identified by the company; and
o legal barriers to entry; or
o any other factors the Board considers relevant,
Where the company is proposing to conduct exploitation overseas due to close
proximity to customers, suppliers and competitors, the Board will consider:
R&D Start Grant Agreement
Particular Conditions 7 SME Agreement Version 7
Version 7.2 - Release Date December 2002
Author: R&D Start Program Management
o the level of commitment to retaining or enhancing the companies R&D
facilities in Australia;
o the mechanisms established to disseminate knowledge and market
intelligence from overseas to the companies operations based in Australia;
o the industry norms in terms of proximity;
o the level of competition in the industry sector and the need to innovate
quickly;
o the nature of the products' inputs which require close contact eg
perishables, knowledge, etc; and
o any other factors the Board considers relevant.
R&D Start Grant Agreement
Particular Conditions 8 SME Agreement Version 7
Version 7.2 - Release Date December 2002
Author: R&D Start Program Management